Filing Flows › Castle Biosciences (CSTL) › Capital expenditures
Castle Biosciences (CSTL) capital expenditures by quarter
Castle Biosciences' capital expenditures were $7.5M in Q3 2026 (third quarter 2026), -13% from Q2 2026. Over the last 5 quarters it ranged from $7.2M (Q4 2025) to $14.8M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $7.5M | -13% | -49% |
| Q2 2026 | $8.7M | +20% | -7% |
| Q4 2025 | $7.2M | -52% | — |
| Q3 2025 | $14.8M | +60% | — |
| Q2 2025 | $9.3M | — | — |
Q3 2026 at a glance
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Castle Biosciences' capital expenditures?
Castle Biosciences' capital expenditures were $7.5M in Q3 2026 (third quarter 2026), -13% from Q2 2026.
How has Castle Biosciences' capital expenditures changed?
Over the last 5 quarters it ranged from $7.2M (Q4 2025) to $14.8M (Q3 2025).